NDAORALTABLET
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORETICYL 50 is a fixed-dose oral tablet combining deserpidine (an alkaloid antihypertensive) and hydrochlorothiazide (a thiazide diuretic), approved in 1959 for the treatment of hypertension. This combination targets blood pressure reduction through dual mechanisms: deserpidine acts as a sympatholytic agent while HCTZ functions as a diuretic. The product represents a legacy antihypertensive regimen from the mid-20th century era of cardiovascular therapy.
LOE Approaching
With LOE approaching and minimal linked job activity, this product faces significant commercial wind-down; team size and investment are likely constrained.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORETICYL 50 offers limited career growth potential given its LOE-approaching status, declining market relevance, and zero linked job opportunities in current market. This assignment is better suited to early-career professionals seeking foundational commercial experience or individuals in portfolio management roles focused on lifecycle optimization and profitable wind-down strategies.
Brand Manager
Worked on ORETICYL 50 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.